## Federica Fioroni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4710042/publications.pdf

Version: 2024-02-01

687363 610901 28 602 13 24 citations h-index g-index papers 31 31 31 1108 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1113-1122.	6.4	152
2	Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients. Thyroid, 2014, 24, 715-726.	4.5	68
3	Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1381-1390.	6.4	50
4	Radiomic Profiling of Head and Neck Cancer: <sup>18</sup> F-FDG PET Texture Analysis as Predictor of Patient Survival. Contrast Media and Molecular Imaging, 2018, 2018, 1-8.	0.8	36
5	Time Evolution of DOTATOC Uptake in Neuroendocrine Tumors in View of a Possible Application of Radioguided Surgery with $\hat{l}^2$ (sup) Decay. Journal of Nuclear Medicine, 2015, 56, 1501-1506.	5.0	26
6	Texture analysis and multiple-instance learning for the classification of malignant lymphomas. Computer Methods and Programs in Biomedicine, 2020, 185, 105153.	4.7	24
7	The Italian multicentre dosimetric study for lesion dosimetry in 223 Ra therapy of bone metastases: Calibration protocol of gamma cameras and patient eligibility criteria. Physica Medica, 2016, 32, 1731-1737.	0.7	22
8	Added diagnostic value of respiratory-gated 4D 18F–FDG PET/CT in the detection of liver lesions: a multicenter study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 102-109.	6.4	22
9	Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. EJNMMI Physics, 2020, 7, 63.	2.7	21
10	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq0 C	) O rgBT /C	Verlock 10 Tf
11	Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. Nuclear Medicine Communications, 2009, 30, 176-182.  Labelling of <mml:math <="" td="" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td>1.1</td><td>18</td></mml:math>	1.1	18
12	id="M1"> <mml:mrow><mml:msup><mml:mrow></mml:mrow><mml:mrow><mml:mn mathvariant="bold-italic">90</mml:mn></mml:mrow></mml:msup></mml:mrow> Y- and <mml:math id="M2" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msup><mml:mrow><mml:mn< td=""><td>0.8</td><td>16</td></mml:mn<></mml:mrow></mml:msup></mml:mrow></mml:math>	0.8	16
13	mathvariant="bold-italic">177Lu-DOTA-Biocor Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 216-231.	njugates 0.7	15
14	Partial volume effect of SPECT images in PRRT with 177Lu labelled somatostatin analogues: A practical solution. Physica Medica, 2019, 57, 153-159.	0.7	14
15	PET systems: the value of added length. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1629-1632.	6.4	12
16	Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT. Cancers, 2022, 14, 592.	3.7	12
17	68Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients. Frontiers in Medicine, 2020, 7, 601853.	2.6	11
18	COMPARISON OF TWO DIFFERENT TYPES OF LIF:MG,CU,P THERMOLUMINESCENT DOSIMETERS FOR DETECTION OF BETA RAYS (BETA-TLDS) FROM 90SR/90Y, 85KR AND 147PM SOURCES. Health Physics, 2011, 100, 515-522.	0.5	10

#	Article	IF	CITATIONS
19	Personnel exposure in labelling and administration of 177Lu-DOTA-D-Phe1-Tyr3-octreotide. Nuclear Medicine Communications, 2011, 32, 947-953.	1.1	10
20	Comparison of different calculation techniques for absorbed dose assessment in patient specific peptide receptor radionuclide therapy. PLoS ONE, 2020, 15, e0236466.	2.5	9
21	4Dâ€PET data sorting into different number of phases: a NEMA IQ phantom study. Journal of Applied Clinical Medical Physics, 2009, 10, 220-231.	1.9	8
22	Effect of image registration on 3D absorbed dose calculations in 177 Lu-DOTATOC peptide receptor radionuclide therapy. Physica Medica, 2018, 45, 177-185.	0.7	7
23	18F-fluorodeoxyglucose positron emission tomographic scan in solid-type p-stage-l pulmonary adenocarcinomas: what can produce false-negative results?â€. European Journal of Cardio-thoracic Surgery, 2017, 51, ezw394.	1.4	6
24	Skin dose saving of the staff in 90Y/177Lu peptide receptor radionuclide therapy with the automatic dose dispenser. Nuclear Medicine Communications, 2016, 37, 1046-1052.	1.1	5
25	DNA damage in lens epithelial cells exposed to occupationally-relevant X-ray doses and role in cataract formation. Scientific Reports, 2020, 10, 21693.	3.3	5
26	Radiation protection procedures in 131I treatments for thyroid cancer in patients requiring hemodialysis. Nuclear Medicine Communications, 2014, 35, 626-630.	1.1	2
27	How direct measurements on worker eyes with Scheimpflug camera can affect lens dose conversion coefficients in interventional radiology. Journal of Radiological Protection, 2021, 41, .	1.1	1
28	Use of Positron Emission Tomography for Target Volume Definition. Current Radiopharmaceuticals, 2009, 2, 144-148.	0.8	0